All In Biotech

Drug Trial Radar · NCT07644442

Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male Subjects

A Single-center, Open-label, Single-dose Phase I Clinical Study to Investigate the Human Mass Balance in Healthy Chinese Adult Male Subjects Following a Single Oral Dose of 300 mg/200 µCi [14C] HMPL-453

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Feb 26, 2025

Primary completion

Mar 14, 2025

Study completion Mar 14, 2025

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of \[14C\]HMPL-453

Conditions

  • Mass Balance Study

Interventions

  • HMPL-453Drug

    D1: 300 mg/200 µCi \[14C\] HMPL-453 Single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Human Mass balanceTime frame: Day-1 ~Day15
  2. Human Mass balanceTime frame: Day-1 ~Day15
  3. Human Mass balanceTime frame: Day-1 ~Day15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.